CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), designed to target inhibitory immune checkpoint molecules, such as programmed death-ligand 1 (PD-L1) and its receptor, programmed death-1 (PD-1), have dramatically changed the treatment landscape in non-small cell lung cancer (NSCLC) (1).